The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 20, 2008
Filed:
Dec. 04, 2002
Silvio Ernesto Perea Rodriguez, Playa, CU;
Osvaldo Reyes Acosta, Playa, CU;
Nelson Francisco Santiago Vispo, Playa, CU;
Yaquelin Puchades Izaguirre, Juanelo, CU;
Ricardo Silva Rodriguez, Playa, CU;
Alejandro Moro Soria, Zoológico, CU;
Alicia Santos Savio, Playa, CU;
Luis Javier González López, Playa, CU;
Belkis González Barrios, Playa, CU;
Silvio Ernesto Perea Rodriguez, Playa, CU;
Osvaldo Reyes Acosta, Playa, CU;
Nelson Francisco Santiago Vispo, Playa, CU;
Yaquelin Puchades Izaguirre, Juanelo, CU;
Ricardo Silva Rodriguez, Playa, CU;
Alejandro Moro Soria, Zoológico, CU;
Alicia Santos Savio, Playa, CU;
Luis Javier González López, Playa, CU;
Belkis González Barrios, Playa, CU;
Centro de Ingenieria Genetica y Biotechologia, Playa, Ciudad de La Habana, CU;
Abstract
This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.